Inventor
CLOZEL MARTINE
CH44 patents
⚠️ This page may combine multiple inventors who share the name “CLOZEL MARTINE”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ACTELION PHARMACEUTICALS LTD
23 patentsUS7285549B2Oct 23, 2007
Sulfamides and their use as endothelin receptor antagonists
ACTELION PHARMACEUTICALS LTD27 citations93
US7094781B2Aug 22, 2006
Sulfamides and their use as endothelin receptor antagonists
ACTELION PHARMACEUTICALS LTD38 citations93
US7763638B2Jul 27, 2010
Substituted 1,2,3,4-tetrahydroisoquinoline derivatives
ACTELION PHARMACEUTICALS LTD24 citations92
US9173881B2Nov 3, 2015
Therapeutic compositions containing macitentan
ACTELION PHARMACEUTICALS LTD8 citations84
US7750040B2Jul 6, 2010
Thiophene derivatives
ACTELION PHARMACEUTICALS LTD17 citations84
US7435815B2Oct 14, 2008
Sulfonylamino-acetic acid derivatives
ACTELION PHARMACEUTICALS LTD10 citations84
US7279578B2Oct 9, 2007
Sulfonylamino-acetic acid derivatives
ACTELION PHARMACEUTICALS LTD11 citations84
US7192950B2Mar 20, 2007
Benzazepines and related heterocyclic derivatives which are useful as orexin receptor antagonists
ACTELION PHARMACEUTICALS LTD15 citations84
US11026927B2Jun 8, 2021
Pharmaceutical combination comprising a selective S1P1 receptor agonist
ACTELION PHARMACEUTICALS LTD4 citations81
US10245253B2Apr 2, 2019
Pharmaceutical combination comprising a selective S1P1 receptor agonist
ACTELION PHARMACEUTICALS LTD6 citations81
US6703392B2Mar 9, 2004
1,2,3,4-tetrahydroisoquinoline derivatives
ACTELION PHARMACEUTICALS LTD20 citations81
US7538109B2May 26, 2009
Quinoxalin-3-one derivatives as orexin receptor antagonists
ACTELION PHARMACEUTICALS LTD7 citations74
US9597331B2Mar 21, 2017
Therapeutic compositions containing macitentan
ACTELION PHARMACEUTICALS LTD3 citations73
US11672783B2Jun 13, 2023
Pharmaceutical combination comprising a selective S1P1 receptor agonist
ACTELION PHARMACEUTICALS LTD2 citations70
US7868012B2Jan 11, 2011
Sulfamides as endothelin receptor antagonists for the treatment of cardiovascular diseases
ACTELION PHARMACEUTICALS LTD4 citations63
US7452896B2Nov 18, 2008
Pyrimidine-sulfamides and their use as endothelian receptor antagonist
ACTELION PHARMACEUTICALS LTD5 citations63
US7323465B2Jan 29, 2008
Alkansulfonamides as endothelin antagonists
ACTELION PHARMACEUTICALS LTD2 citations63
US7091201B2Aug 15, 2006
Arylalkane-sulfonamides having endothelin-antagonist activity
ACTELION PHARMACEUTICALS LTD2 citations63
US7375227B2May 20, 2008
Quinoline derivatives
ACTELION PHARMACEUTICALS LTD2 citations62
US6815451B2Nov 9, 2004
1,2,3,4-Tetrahydroisoquinolines derivatives as urotensin II receptor antagonists
ACTELION PHARMACEUTICALS LTD2 citations62
US11723896B2Aug 15, 2023
Pharmaceutical combination comprising ponesimod
ACTELION PHARMACEUTICALS LTD0 citations58
US6951856B2Oct 4, 2005
Arylethene-sulfonamides
ACTELION PHARMACEUTICALS LTD1 citations52
US7238685B2Jul 3, 2007
Benzo-fused heterocycles as endothelin antagonists
ACTELION PHARMACEUTICALS LTD2 citations49
HOFFMANN LA ROCHE
10 patentsUS5292740AMar 8, 1994
Sulfonamides
HOFFMANN LA ROCHE180 citations99
US5420129AMay 30, 1995
Phenylsulfonylamide pyrimidine
HOFFMANN LA ROCHE132 citations98
US5541186AJul 30, 1996
Sulfonylaminopyrimidines
HOFFMANN LA ROCHE86 citations96
US5270313ADec 14, 1993
Sulfonamides and uses
HOFFMANN LA ROCHE81 citations94
US6133442AOct 17, 2000
Aryl- and hetaryl-sulfonamide derivatives, their preparation and their use as endothelin antagonists
HOFFMANN LA ROCHE22 citations92
US6004965ADec 21, 1999
Sulfonamides
HOFFMANN LA ROCHE32 citations92
US5837708ANov 17, 1998
Sulphonamides
HOFFMANN LA ROCHE21 citations92
US5696116ADec 9, 1997
Pharmaceutical composition which contains a renin angiotensin system inhibitor and an endothelin antagonist
HOFFMANN LA ROCHE36 citations87
US5962682AOct 5, 1999
Aryl- and hetaryl-sulfonamide derivatives, their preparation and their use as endothelin antagonists
HOFFMANN LA ROCHE12 citations74
US5856484AJan 5, 1999
Sulfonylaminopyrimidine carboxylic acid derivatives having endothelin inhibiting activity
HOFFMANN LA ROCHE10 citations74
CLOZEL MARTINE
3 patentsUS8809334B2Aug 19, 2014
Therapeutic compositions containing macitentan
CLOZEL MARTINE36 citations97
US8268847B2Sep 18, 2012
Therapeutic compositions comprising a specific endothelin receptor antagonist and a PDE5 inhibitor
CLOZEL MARTINE16 citations83
US8541433B2Sep 24, 2013
Combination comprising macitentan and paclitaxel for treating multi-drug resistant ovarian cancer
CLOZEL MARTINE8 citations80
IDORSIA PHARMACEUTICALS LTD
2 patentsUS11787782B2Oct 17, 2023
Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
IDORSIA PHARMACEUTICALS LTD5 citations82
US11174247B2Nov 16, 2021
Combinations of a 4-pyrimidinesulfamide derivative with active ingredients for the treatment of endothelin related diseases
IDORSIA PHARMACEUTICALS LTD6 citations81